Colloidal carriers diverge depending on their composition, ability to incorporate drugs
and applicability, but the common feature is the small average particle size. Among the carriers with
the potential nanostructured drug delivery application there are SLN and NLC. These nanostructured
systems consist of complex lipids and highly purified mixtures of glycerides having varying particle
size. Also, these systems have shown physical stability, protection capacity of unstable drugs, release
control ability, excellent tolerability, possibility of vectorization, and no reported production
problems related to large-scale. Several production procedures can be applied to achieve high association
efficiency between the bioactive and the carrier, depending on the physicochemical properties
of both, as well as on the production procedure applied. The whole set of unique advantages
such as enhanced drug loading capacity, prevention of drug expulsion, leads to more flexibility for
modulation of drug release and makes Lipid-based nanocarriers (LNCs) versatile delivery system
for various routes of administration. The route of administration has a significant impact on the
therapeutic outcome of a drug. Thus, the non-invasive routes, which were of minor importance as
parts of drug delivery in the past, have assumed added importance drugs, proteins, peptides and
biopharmaceuticals drug delivery and these include nasal, buccal, vaginal and transdermal routes.
The objective of this paper is to present the state of the art concerning the application of the lipid
nanocarriers designated for non-invasive routes of administration. In this manner, this review presents
an innovative technological platform to develop nanostructured delivery systems with great
versatility of application in non-invasive routes of administration and targeting drug release.
NANO-SPONGE NOVEL DRUG DELIVERY SYSTEM AS CARRIER OF ANTI-HYPERTENSIVE DRUG